radiprodil + midazolam + rosuvastatin + warfarin + digoxin + omeprazole

This is a **combination of six pharmaceutical agents**: - **Radiprodil**: An investigational small molecule, negative allosteric modulator of the NR2B subunit of the NMDA (N-methyl-D-aspartate) receptor; studied for epilepsy and GRIN-related neurodevelopmental disorders. - **Midazolam**: A benzodiazepine sedative, GABA-A receptor positive allosteric modulator, used for anesthesia and acute seizure management. - **Rosuvastatin**: A statin drug, HMG-CoA reductase inhibitor, used for lowering cholesterol. - **Warfarin**: A vitamin K antagonist and oral anticoagulant, inhibits vitamin K epoxide reductase (VKORC1), used in thrombosis prevention. - **Digoxin**: A cardiac glycoside, inhibits Na+/K+ ATPase, used in heart failure and atrial fibrillation. - **Omeprazole**: A proton pump inhibitor (PPI), inhibits H+/K+ ATPase in gastric parietal cells, used for acid-related gastrointestinal disorders. This specific **combination is not an approved fixed-dose or branded drug product**. The combination is sometimes used in pharmacokinetic drug-drug interaction studies due to the distinct metabolic and transporter pathways of the individual drugs[2]. Clinical co-administration may only occur in rare or research settings, as the combination poses significant risk for drug-drug interactions, especially concerning warfarin, rosuvastatin, and digoxin metabolism via CYP pathways and transporter proteins[4][2][6].